Poly(ethylene glycol) conjugated drugs and prodrugs: A comprehensive review

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 17, Issue 2, 2000, Pages 101-161

  Greenwald, Richard B ^a   Conover, Charles D ^a   Choe, Yun H ^a  

^a Enzon Incorporated   (United States)

Author keywords

Anticancer drug conjugates; Camptothecin; EPR effect; Paclitaxel; Poly(ethylene glycol); Prodrugs

Indexed keywords

AMIDE; CAMPTOTHECIN; CARBAMIC ACID DERIVATIVE; CARBONIC ACID DERIVATIVE; DOXORUBICIN; HYDRAZONE DERIVATIVE; MACROGOL; MACROLIDE; PACLITAXEL; PODOPHYLLOTOXIN DERIVATIVE; PRODRUG;

CHEMICAL STRUCTURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HALF LIFE TIME; MOLECULAR WEIGHT; REVIEW;

EID: 0034060544     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevtherdrugcarriersyst.v17.i2.20     Document Type: Review

References (148)

1. The IUPAC nomenclature for poly(ethylene) glycol is α-hydro-ω-hydroxypoly(oxy-1,2-ethanediyl). PEG in this review will refer to the diol unless otherwise specified. mPEG will refer to the mono methyl ether, α-hydroxy-ω-methylpoly (oxy-1,2-ethanediyl).
2. Harris, J. M., Ed., Poly(ethylene glycol) Chemistry, Biotechnical and Biomedical Applications, New York: Plenum Press, 1992.
3. Nucci, M. L., Shorr, E., and Abuchowski, A., The therapeutic value of poly(ethylene glycol)-modified proteins, Adv. Drug Deliv. Rev., 6, 133, 1991.
4. Delgado, C., Francis, G. E., and Fisher, D., The uses and properties of PEG-linked proteins, Crit. Rev. Ther. Drug Carrier Syst., 9, 249, 1992.
5. Katre, N. V., The conjugation of proteins with polyethylene glycol and other polymers, Adv. Drug Deliv. Rev., 10, 91, 1993.
6. Hooftman, G., Herman, S., and Schacht, E., Review: Poly(ethylene glycols) with reactive endgroups, II. Practical consideration for the preparation of protein-PEG conjugates, script J sign. Bioact. Compat. Polym., 11, 135, 1996.
7. Zalipsky, S., Chemistry of polyethylene glycol conjugates with biologically active molecules, Adv. Drug Deliv. Rev., 16, 157, 1995.
8. Ranucci, E., Spagnoli, G., Latini, R., Bernasconi, R., and Ferruti, P., On the suitability of urethane bonds between the carrier and the drug moiety in poly(ethyleneglycol)-based oligimeric prodrugs, script J sign. Biomater. Sci. Polym. Ed., 6, 133, 1994.
9. Caliceti, P., Monfardini, C., Sartore, L., Schiavon, O., Baccichetti, F., Carlassare, F., and Veronese, F. M., Preparation and properties of monomethoxy poly(ethylene glycol) doxorubicin conjugates linked by an amino acid or a peptide as spacer, IL Farmaco, 48, 919, 1993.
10. Ferruti, P., Molz, P., Ringsdorf, H., and Rusconi, L., Polymer derivatives of daunorubicin as drug delivery systems in antitumor chemotherapy, Int. Symp. Polymers in Medicine, Porto Cerva, Sardinia 21, 1982. (Cited by R. Duncan, CRC Grit. Rev. Ther. Drug Carrier Syst., 1, 281, 1985, Ref. 205).
11. Ferruti, P., Molz, P., Ringsdorf, H., and Rusconi, L., Polymer derivatives of daunorubicin as drug delivery systems in antitumor chemotherapy, Int. Symp. Polymers in Medicine, Porto Cerva, Sardinia 21, 1982. (Cited by R. Duncan, CRC Grit. Rev. Ther. Drug Carrier Syst., 1, 281, 1985, Ref. 205).
12. Herman, S., Hooftman, G., and Schacht, E., Poly(ethylene glycol) with reactive end-groups, I. Modification of proteins, script J sign. Bioactive Compat. Polym,. 10, 145, 1995.
13. Zalipsky, S., Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates, Bioconjug. Chem., 6, 150, 1995.
14. Zalipsky, S., Gilon, C., and Zilkha, A., Attachment of drugs to polyethylene glycols, Eur. Polym. script J sign., 19, 1177, 1983.
15. Pang, S. J., Final report on the safety assessment of polyethylene glycols (PEGs)-6,-8,-32, -75,-150,-14M,-20M, script J sign. Am. College Tax., 12, 429, 1993.
16. Yamaoka, T., Tabata, Y., and Ikada, Y., Comparison of body distribution of poly(vinyl alcohol) with other water-soluble polymers after intravenous administration, script J sign. Pharm. Pharmacol., 47, 479, 1995.
17. Smyth, Jr., H. F., Carpenter, C. P., and Shaffer, C. B., The toxicity of high molecular weight polyethylene glycols; chronic oral and parenteral administration, script J sign. Am. Pharm. Assoc., 36, 157, 1947.
18. Greenwald, R. B., Drug delivery systems: Anticancer prodrugs and their polymeric conjugates, Exp. Opin. Ther. Patents, 7, 601, 1997.
19. The terms PEG-low mw organic molecule and PEG-drug are used interchangeably in this paper.
20. Yamaoka, T., Tabata, Y., and Ikada, Y., Distribution and tissue uptake of polyethylene glycol with different molecular weights after intravenous administration to mice, script J sign. Pharm. Sci., 83, 601, 1994.
21. Harris, F. W., Controlled release from polymers containing pendent bioactive substituents, in Medical Applications of Controlled Release, Vol. 7, Langer, R. S. and Wise, D. L., Eds., Boca Raton, FL: CRC Press, 1984, 103.
22. Ringsdorf, H., Structure and properties of pharmacologically active polymers, script J sign. Polym. Sci.: Symp. No. 51, 135, 1975.
23. Greenwald, R. B., Gilbert, C. W., Pendri, A., Conover, C. D., Xia, J., and Martinez, A., Drug delivery systems: Water soluble taxol 2-poly(ethylene glycol) ester prodrugs - design and in vivo effectiveness, script J sign. Med. Chem, 39, 424, 1996.
24. Duncan, R., Drug-polymer conjugates: Potential for improved chemotherapy, Anticancer Drugs, 3, 175, 1992.
25. Takakura, Y. and Hashida, M., Macromolecular drug carriers systems in cancer chemotherapy: Macromolecular prodrugs, Crit. Rev. Oncology Hematol., 18, 207, 1995.
26. Stella, V.J., Charman, W. N. A., and Naringrekar, V. H., Prodrugs, do they have advantages in clinical practice? Drugs, 29, 455, 1985.
27. Bundgaard, H., Novel chemical approaches in prodrug design, Drugs Fut., 16, 443, 1991.
28. Sinhababu, A. K. and Thakker, D. R., Prodrugs of anticancer agents, Adv. Drug Deliv. Rev., 19, 241, 1996.
29. Bundgaard, H., The double prodrug concept and its applications, Adv. Drug Deliv. Rev., 3, 39, 1989.
30. Ferruti, P., Tanzi, M., Rusconi, L., and Cecchi, R., Succinic half-esters of poly(ethylene glycol)s and their benzotriazole and imidazole derivatives as oligomeric drug-binding matrices, Makromol. Chem., 24, 2183, 1981.
31. Traber, M., Thellmari, C., Rindler, M., and Kayden, H., Uptake of intact TPGS (d-a-tocopheryl polyethylene glycol 1000 succinate), a water-miscible form of vitamin E by human cells in vitro, Am. script J sign. Clin. Nutr., 48, 605, 1988.
32. Traber, M., Kayden, H. J., Green, J. B., and Green, M. H., Absorbtion of water-miscible forms of vitamin E in a patient with cholestasis and in thoracic duct-cannulated rats, Am. script J sign. Clin. Nutr., 44, 914, 1986.
33. Foroutan, S. M. and Watson, D. G., Synthesis and characterisation of polyethylene glycol conjugates of hydrocortisone as potential prodrugs for ocular steroid delivery, Int. script J sign. Pharmaceut., 157, 103, 1997.
34. Foroutan, S. M. and Watson, D. G., The in vitro evaluation of polyethylene glycol esters of hydrocortisone 21-succinatge as ocular prodrugs, Int. script J sign. Pharmaceutics, 182, 79, 1999.
35. Molteni, V., Annunziata, R., Cinquini, M., Cozzi, F., and Benaglia, M., Soluble polymer-supported synthesis of imines and ß-lactams, Tetrahedron Lett., 39, 1257, 1998.
36. Cruz, M. L. and Gil, M. H., Antituberculosis macromolecular prodrugs, Part 1. Isoniazid conjugates with poly(ethylene glycol) derivatives, script J sign. Bioactive Compat. Polym., 13, 146, 1998.
37. Shen, W.-C. and Ryser, H. J.-P., cis-Aconityl spacer between daunomycin and macromolecular carriers: A model of pH-sensitive linkages releasing drug from a lysosomatic conjugate, Biochem. Biophys. Res. Commun., 102, 1048, 1981.
38. Aldersley, M. F., Kirby, A. J., Lancaster, P. W., McDonald, R. S., and Smith, C. R., Intra-molecular catalysis of amide hydrolysis by the carboxy-group. Rate determining proton transfer from external general acids in the hydrolysis of substituted maleamic acids, script J sign. Chem. Soc. Perkin II, 1487, 1974.
39. Kluger, R., Chin, J., and Choy, W.-W., Carboxylic acid participation in amide hydrolysis; Reactivity of intermediates in the internally catalyzed hydrolysis of script N sign-substituted 2,3-dimethylmaleamic acids, script J sign. Am. Chem. Soc., 101, 6976, 1979.
40. Dal Pozzo, A. and Acquasaliente, M., New highly water-soluble phenytoin prodrugs, Int. script J sign. Pharmaceut., 81, 263, 1992.
41. Desai, N. P., Soon-Schiong, P., and Sandford, P. A., Water soluble polymeric carriers for drug delivery, U. S. Patent 5, 648, 506, 1997.
42. Pendri, A., Martinez, A., Xia, J., Shorr, R. G., and Greenwald, R. B., Poly(ethylene glycol) fluorescent linkers, Bioconjug. Chem., 6, 596, 1995.
43. Bentley, M., Chung, B., Ellis, W., and McGreevy, P., Peg-linked artemisinin antimalarials, Polym. Repr., 38, 584, 1997.
44. Vyas, D. M., Paclitaxel (Taxol®) formulation and prodrugs, The Chemistry and Pharmacology of Taxol and its Derivatives, Farina, V., Ed., Elsevier Science B. V., 1995.
45. Greenwald, R. B., Pendri, A., Bolikal, D., and Gilbert, C. W., Highly water soluble taxol derivatives: 2-polyethyleneglycol esters as potential prodrugs, Bioorg. Med. Chem. Lett., 4, 2465, 1994.
46. Enzon, Inc. Unpublished results.
47. Ohya, Y., Kuroda, H., Hirai, K., and Ouchi, T., Synthesis and cytotoxic activity of conjugates of monomethoxy-poly(ethylene glycol) end-capped with doxorubicin via ester, amide or Schiffs base bond, script J sign. Bioactive Compat. Polym., 10, 51, 1995.
48. Lee, H.-K. and Zhu, T., Water soluble rapamycin esters, U. S. Patent 5, 780, 462, 1998.
49. Chang, P. S. and Cho, H., Water-soluble polymer-tacrolimus conjugated compounds and process for preparing the same, U. S. Patent 5, 922, 729, 1999.
50. Cecchi, R., Rusconi, L., Tanzi, M. C., Danusso, F., and Ferruti, P., Synthesis and pharmacological evaluation of poly(oxyethylene) derivatives of 4-isobutylphenyl-2-propionic acid (Ibuprofen), script J sign. Med. Chem., 24, 622, 1981.
51. Sartore, L., Peroni, I., Ferruti, P., Latini, R., and Bernasconi, R., script J sign. Biomater. Sci. Polym. Ed., 8, 741, 1997.
52. Chedini, N., Ferruti, P., Andrisano, V., Cesaroni, M. R., and Scapini, G., Oligomeric derivatives of 3a, 7b-dihydroxy-5b-cholan-24-oic acid (ursodeoxycholic acid), Syn. Commun., 13, 701, 1983.
53. Ranucci, E., Sartore, L., Peroni, I., Latini, R. Bernasconi, R., and Ferutti, P., Pharmokinetic results in naproxen prodrugs based on poly(ethylene glycol)s, script J sign. Biomater. Sci. Polym. Ed., 6, 141, 1994.
54. Ouchi, T., Yuyama, H., and Vogl, O., Syntheses of 5-fluorouracil-terminated monomethoxypoly (ethylene glycols), their hydrolysis behavior and their antitumor activities, script J sign. Macromol. Sci. Chem., A24(9), 1011, 1987.
55. Ouchi, T. and Yuyama, H., Synthesis of poly(ethylene glycols)-capped with 5-fluorouracil units through ester bonds and their antitumor activities, script J sign. Polym. Sci., Part C: Polymer Lett., 25, 279, 1987.
56. Ouchi, T., Yuyama, H., and Vogl, O., Synthesis of poly(ethylene glycol)-bound 3-(5-fluoro-uracil-1-yl) propanoic acid, its hydrolysis reactivity and antitumor activity, Makromol. Chem. Rapid Commun., 6, 815, 1985
57. Dal Pozzo, A., Acquasaliente, M., Donzelli, G., Delor, F., and Ferruti, P., Synthesis and antimicrobial properties of new aroyl-acrylic esters of polyethylene glycols, Il Farmaco Ed. Sci., 41, 622, 1986.
58. Mincheva, Z., Stambolieva, N., and Rashkov, I., Preparation and properties of di, tri- and poly-(ethyleneglycol) esters of 2-benzoxazolon-3-yl-acetic acid, Eur. Polym. script J sign., 30, 761, 1994.
59. Bonina, F. P., Montenegro, L., De Caprariis, P., Palagiano, F., Trapani, G., and Liso, G., In vitro and in vivo evaluation of polyoxyethylene indomethacin esters as dermal prodrugs, script J sign. Controlled Rel. 34, 223, 1995.
60. Ashton, P., Smith, T. J., Glavinos, P. G., Conklin, Jr., J. D., Crooks, P. A., Riggs, R. M., Cynkowski, T., and Cynkowski, G., Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents, U.S. Patent 5, 681, 964, 1997.
61. Weiner, B., Havron, A., and Zilkha, A., Salicylates attached to polymers, Israeli script J sign. Chem., 12, 863, 1974.
62. Weiner, B. and Zilkha, A., Polyethylene glycol derivatives of procaine, script J sign. Med. Chem., 16, 573, 1973.
63. Weiner, B., Zilkha, A., Porath, G., and Grunfeld, Y., Atropine attached to polyethylene glycols, Eur. script J sign. Med. Chem. Chemica Therapeutica, 6, 525, 1976.
64. Greenwald, R. B., Pendri, A., and Bolikal, D., Highly water-soluble taxol derivatives: 7-polyethylene glycol carbamates and carbonates, script J sign. Org. Chem., 60, 331, 1995.
65. Greenwald, R. B., Pendri, A., Martinez, A., Gilbert, C., and Bradley, P., PEG thiazolidine-2-thione, a novel reagent for protein modification: Conjugation of bovine hemoglobin, Bioconjug. Chem., 7, 638, 1996.
66. Ouchi, T., Hagihara, Y., Takahashi, K., Takano, Y., and Igarashi, I., Synthesis and antitumor activity of poly (ethylene glycol)s linked to 5-fluorouracil via a urethane or urea bond, Drug Des. Discov., 9, 93, 1992.
67. Pendri, A., Gilbert, C. W., Soundararajan, S., Bolikal, D., Shorr, R. G. L., and Greenwald, R. B., PEG modified anticancer drugs: Synthesis and biological activity, script J sign. Bioactive Compat. Polym., 11, 122, 1996.
68. Tannock, I. F. and Rotin, D., Acid pH in tumors and its potential for therapeutic exploitation, Cancer Res., 49, 4373, 1989.
69. Ulbrich, K., Strohalm, J., and Kopecek, J., Poly (ethylene glycol)s containing enzymatically degradable bonds, Makromol. Chem., 187, 1131, 1986.
70. Chakravarty, P. K., Carl, P. L., Weber, M. J., and Katzenellenbogen, J. A., Plasmin-activated prodrugs for cancer chemotherapy, 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin, script J sign. Med. Chem., 26, 638, 1983 and references cited.
71. Jungheim, L. N. and Shepard, T. A., Design of antitumor prodrugs: Substrates for antibody targeted enzymes, Chem. Rev., 94, 1553, 1994.
72. Senter, P., Svensson, H., Schreiber, G., Rodriguez, J., and Vrudhula, V., Poly(ethylene glycol)-doxorubicin conjugates containing b-lactamase-sensitive linkers, Bioconjug. Chem., 6, 389, 1995.
73. Nichifor, M., Coessens, V., and Schacht, E. H., Macromolecular prodrugs of 5-fluorouracil, 1: Synthesis and hydrolytic stability, script J sign. Bioactive Compat. Polym., 10, 199, 1995.
74. Nichifor, M., Schacht, E. H., and Seymour, L. W., Macromolecular prodrugs of 5-fluorouracil 2: Enzymatic degradation, script J sign. Controlled Rel., 39, 79,1996.
75. Kingsbury, W. D., Boehm, J. C., Mehta, R. J., Groppel, S. F., and Gilvarg, C., A novel peptide delivery system involving peptidase activated prodrugs as antimicrobial agents, synthesis and biological activity of peptidyl derivatives, script J sign. Med. Chem., 27, 1447, 1984.
76. Henderson, G., Folates and Pterins, Vol. 3, Blakley, R. L., and Whitehead, V. M., Eds., 207, New York: John Wiley, 1986.
77. Rosowsky, A., Forsch, R., Uren, J., and Wick, M., Methotrexate analogues, 14. Synthesis of new γ-substituted derivatives as dihydroflolate reductase inhibitors and potential anticancer agents, script J sign. Med. Chem., 24, 1450, 1981.
78. Johnson, D. A., Laguzza, B. C., and Scott, W., Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers, U. S. Patent 5, 028, 697, 1991.
79. Eknoian, M. W., Worley, S. D., and Harris, J. M., New biocidal script N sign-haloamine PEG polymers, script J sign. Bioactive Polym., 13, 136, 1998.
80. Cornforth, J. W., Morgan, E. D., Potts, K. T., and Rees, R. J. W., Preparation of antituberculous polyoxyethylene ethers of homogeneous structure, Tetrahedron, 29, 1659, 1973.
81. Khachadurian, A. K., Fung, C. H., Van Es, T., and Davis, F. F., Polyoxyethylated cholesterol derivatives - organic synthesis, cellular uptake and effect on lipid metabolism in cultured skin fibroblasts, Biochim. Biophys. Acta, 665, 434, 1981.
82. Weiner, B. and Zilkha A., Synthesis of indole derivatives attached to poly(ethylene oxides), script J sign. Macromol. Sci. Chem., All, 1191, 1977.
83. Rashkov, I., Angelova, N., and Manolova, N., Preparation and properties of poly(oxyethylene)s with 5-chloro-8-quinolinoxyl end-groups, Eur. Polym. script J sign., 29, 1407, 1993.
84. Seymour, L. W., Duncan, R., Strohalm, J., and Kopecek, J., Effect of molecular weight (Mw) of script N sign-(2-hydroxypropyl) methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats, script J sign. Biomed. Mater. Res., 21, 1341, 1987.
85. Seymour, L. W., Ulbrich, K., Strohalm, J., Kopecek, J., and Duncan, R., The pharmacokinetics of polymer-bound adriamycin, Biochem. Pharmacol., 39, 1125, 1990.
86. Duncan, R. and Spreanco, F., Polymer conjugates, pharmacokinetic considerations for design and development, Clin. Pharmacokinet., 27, 290, 1994.
87. Seymour, L. W., Miyamoto, H., Brereton, M., Strohalm, K., Ulbrich, K., and Duncan, R., Influence of molecular weight on passive tumour accumulation of a soluble acromolecular drug carrier, Eur. script J sign. Cancer, 31A, 766, 1995.
88. Somack, R., Saifer, M. G. P., and Williams, L. D., Preparation of long acting superoxide dismutase using high molecular weight polyethylene glycol (41,000-72,000 Daltons), Free Radical Res. Comm., 12-13, 553, 1991.
89. Knauf, M. J., Bell, D. P., Hirtzer, P., Lou, Z. P., Young, J. D., and Katre, N. V., Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water soluble polymers, script J sign. Biol. Chem., 263, 15064, 1988.
90. Maeda H., SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy, Adv. Drug Deliv. Rev., 6, 181, 1991.
91. Maeda, H., Seymour, L. W., and Miyamoto, Y., Conjugates of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo. Bioconjug. Chem., 3, 351, 1992.
92. Noguchi, Y., Wun, J., Duncan, R., Strohalm, R., Ulbrich, K., Akaike, T., and Maeda, H., Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissues, Jpn. script J sign. Cancer Res., 89, 307, 1998.
93. Conover, C. D., Greenwald, R. B., Pendri, A., Gilbert, C. W., and Shum, K. L., Camptothecin delivery systems: Enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker, Cancer Chemother. Pharmacol, 42, 407, 1998.
94. Li, C., Yu, D., Newman, R., Cabral, F., Stephens, L. C., Hunter, N., Milas, L., and Wallace, S., Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate, Cancer Res., 58, 2404, 1998.
95. Li, C., Yu, D., Inoue, T., Yang, D. J., Milas, L., Hunter, N., Kim, E., and Wallace, S., Synthesis and evaluation of water-soluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrug, Anticancer Drugs, 7, 642, 1996.
96. Carl, P. L., Chakravarty, P. K., and Katzenellenbogen J. A., A novel connector linkage applicable in prodrug design, script J sign. Med. Chem., 24, 479, 1981.
97. Greenwald, R. B., Pendri, A., Conover, C. D., Lee, C., Choe, Y. H., Gilbert, C., Martinez, A., Xia, J., Wu, D., and Hsue, M., Camptothecin-20-PEG ester transport forms: The effect of spacer groups on antitumor activity, Bioorg. Med. Chem., 6, 551, 1998.
98. Pendri, A., Conover, C. D., and Greenwald, R. B., Antitumor activity of paclitaxel-2′-glycinate conjugated to poly(ethylene glycol): A water-soluble prodrug, Anticancer Drug Des., 13, 387, 1998.
99. Deutsch, H. M., Glinski, J. A., Hernandez, M., Haugwitz, R. D., Narayan, V., Suffness, M., and Zalkow, L. H., Synthesis of congeners and prodrugs, 3. Water-soluble prodrugs of taxol with potent antitumor activity, script J sign. Med. Chem., 32, 788, 1989.
100. Zhao, Z., Kingston, D. G. I., and Crosswell, A. R., Modified taxols, 6. Preparation of water-soluble prodrugs of taxol, script J sign. Nat. Prod., 54, 1607, 1991.
101. Matthew, A. E., Mejillano, M. R., Nath, J. P., Himes, R. H., and Stella, V. J., Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity, script J sign. Med. Chem., 35, 145, 1992.
102. Hess, R., Localization of a cathepsin-like and aminopeptidase activity in various solid tumor transplants, Cancer Res., 20, 940, 1960.
103. Keppler, D., Fondanoche, M. C., Dalet-Fumeron, V., Pagano, M., and Burtin, P., Immunohistochemical and biochemical study of a cathepsin B-like proteinase in human colonic cancers, Cancer Res., 48, 6855, 1988.
104. Recklies, A. D., Tiltman, K. J., Stoker, A. M., and Poole, A. R., Secretion of proteinases from malignant and nonmalignant human breast tissue, Cancer Res., 40, 550, 1980.
105. Baurain, R., Masquelier, M., Deprez-De Campaneere, D., and, Trouet, A., Amino acid and dipeptide derivatives of daunorubicin, 2. Cellular pharmacology and antitumor activity on L1210 leukemic cells in vitro and in vivo, script J sign. Med. Chem., 23, 1171, 1980.
106. Potmesil, M., Camptothecins: From bench research to hospital wards, Cancer Res., 54, 1431, 1994.
107. Bedeschi, A., Candiani, I., Geroni, C., and Capolongo, L., Water-soluble camptothecin derivatives, Drugs Fut., 22, 1259, 1997.
108. Wall, M. and Wani, M. C., Camptothecin and taxol: Discovery to clinic, 13th Bruce F. Cain Memorial Award Lecture, Cancer Res., 55, 753, 1995.
109. Rao Vishnuvajjala, B. and Garzon-Aburbeh, A., Water soluble prodrugs of camptothecin, U. S. Patent 4, 943, 579, 1990.
110. Wall, M. E., Wani, M. C., Nicholas, W., Manikumar, G., Tele, C., Moore, L., Truesdale, A., Leitner, P., and Besterman, J. M., Plant antitumor agents, 30. Synthesis and structure activity of novel camptothecin analogs, script J sign. Med. Chem., 36, 2689, 1993.
111. Greenwald, R. B., Pendri, A., Conover, C., Gilbert, C., Yang, R., and Xia, J., Drug delivery systems, 2. Camptothecin 20-O-poly(ethylene glycol) ester transport forms, script J sign. Med. Chem., 39, 1938, 1996.
112. Conover, C. D., Pendri, A., Lee, C., Gilbert, C. W., Shum, K. L., and Greenwald, R. B., Camptothecin delivery systems: The antitumor activity of a camptothecin-20-O-polyethylene glycol ester transport form, Anticancer Res., 17, 3361, 1997.
113. Cao, Z., Harris, N., Kozielski, A., Vardeman, D., Stehlin, J. S., and Giovanella, B., Alkyl esters of camptothecin and 9-nitrocamptothecin: Synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity, script J sign. Med. Chem., 41, 31, 1998.
114. Bundgaard, H., Falch, E., and Jensen, E., A novel solution-stable, water-soluble prodrug type for drugs containing a hydroxyl or NH-acidic group, script J sign. Med. Chem., 32, 2503, 1989.
115. Greenstein, J. P. and Winitz, M., Chemistry of the Amino Acids, Vol. 1, New York: John Wiley, 498, 1961.
116. Martinez, A. J. and Greenwald, R. B., Method of preparing polyalkylene oxide carboxylic acids, U.S. Patent 5, 605, 976, 1997.
117. Bernhard, S. A., Berger, A., Carter, J. H., Katchalski, E., Sela, M., and Shalitin, Y., Cooperative effects of functional groups in peptides, I. Aspartyl-serine derivatives, script J sign. Am. Chem. Soc., 84, 2421, 1962.
118. Mitra Tadayoni, B. M., Friden, P. M., Walus, L. R., and Musso, G. F., Synthesis, in vitro kinetics, and in vivo studies on protein conjugates of AZT: Evaluation as a transport system to increase brain delivery, Bioconjug. Chem., 4, 139, 1993.
119. Gogate, U. S., Repta, A. J., and Alexander, J., script N sign-(acyloxyalkoxycarbonyl) derivatives as potential prodrugs of amines, I. Kinetics and mechanism of degradation in aqueous solutions, Int. script J sign. Pharm., 40, 235, 1987.
120. Fife, T. H. and DeMark, B. R., Intramolecular nucleophilic aminolysis of aliphatic esters, cyclization of methyl 2-aminomethylbenzoate to phthalimidine, script J sign. Am. Chem. Soc., 98, 6978, 1976.
121. Saari, W. S., Schwering, J. E., Lyle, P. A., Smith, S. J., and Englehardt, E. L., Cyclization-activated prodrugs: Basic carbamates of 4-hydroxy anisole, script J sign. Med. Chem., 33, 97, 1990.
122. Soyez, H., Schacht, E., and Vanderkerken, S., The crucial role of spacer groups in macro-molecular prodrug design, Adv. Drug Deliv. Rev., 21, 81, 1996.
123. Conover, C. D., Greenwald, R. B., Pendri, A., and Shum, K. L., Camptothecin delivery systems: The utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs, Anticancer Drug Des., 14, 499, 1999.
124. Han, H., Oh, D., and Amidon, G. L., Cellular uptake mechanism of amino acid ester pro-drugs in Caco-2/hPEPT1 cells over expressing a human peptide transporter, Pharm. Res., 15, 1382, 1998.
125. Balimane, P. V., Tamai, I., Guo, A., Nakanishi, T., Kitada, H., Leibach, F. H., Tsuji, A., and Sinko, P. J., Direct evidence for peptide transporter (PepT1)-mediated uptake of a non-peptide prodrug, valacyclovir, Biochem Biophys. Res. Commun., 250, 246 (1998).
126. Murakami, Y., Tabata, Y., and Ikada, Y., Tumor accumulation of poly(ethylene glycol) with different molecular weights after intravenous injection. Drug Deliv., 4, 23, 1997.
127. Ward, R. S., The synthesis of lignans and neolignans. Chem. Soc. Rev., 11, 75, 1982.
128. Sackett, D. L. Podophyllotoxin, steganicin and combretastatin: Natural products that bind at the colchicirie site of tubulin, Pharmac. Ther., 59, 163, 1993.
129. Seidlova-Masinova, V., Malinsky, J., and Santavy, F., The biological effects of some podophyllin compounds and their dependence on chemical structure, script J sign. Natl. Cancer Inst., 18, 359, 1957.
130. Greenspan, E. M., Colsky, J., Schoenbach, E. B., and Shear, M. J., Response of patients with advanced neoplasms to the intravenous administration of a-peltatin, script J sign. Natl. Cancer Inst., 14, 1257, 1954.
131. Levy, R. K., Hall, I. H., and Lee, K-H., Antitumor agents LXII: Synthesis and biological evaluation of podophyllotoxin esters and related derivatives, script J sign. Pharm. Sci., 72, 1158, 1983.
132. Greenwald, R. B., Conover, C. D., Pendri, A., Choe, Y. H., Martinez, A., Wu, W., Guan, S., Yao, Z., and Shum, K. L., Drug delivery of anticancer agents: Water-soluble 4-poly(ethylene glycol) derivatives of the lignan, podophyllotoxin, script J sign. Controlled Rel., 61, 281, 1999.
133. Rodrigues, P. C A., Beyer, U., Schumacher, P., Roth, T., Fiebig, H. H., Unger, C., Messori, L., Orioli, P., Paper, D. H., Mulhaupt, R., and Kratz, F., Acid-sensitive polyethylene glycol conjugates of doxorubicin: Preparation, in vitro efficacy and intracellular distribution, Bioorg. Med. Chem., 17, 2517, 1999.
134. Greenwald, R. B., Pendri, A., Conover, C. D., Zhao, H., Choe, Y. H., Martinez, A., Shum, K., and Guan, S., Drug delivery systems employing 1,4-or 1,6-elimination: Poly(ethylene glycol) prodrugs of amine containing compounds, script J sign. Med. Chem., 42, 3657, 1999.
135. Denny, W. A. and Wilson, W. R., The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies, script J sign. Pharm. Pharmacol., 50, 387, 1998.
136. Wakselman, M., 1,4- and 1,6-eliminations from hydroxy and amino-substituted benzyl systems: Chemical and biochemical applications, Nouveau script J sign. Chemie, 7, 439, 1983.
137. Shan, D., Nicholaou, M. G., Borchardt, R. T., and Wang, B., Prodrug strategies based on intramolecular cyclization reactions, script J sign. Pharm. Sci., 86, 765, 1997.
138. Testa, B. and Mayer, J. M., Design of intramolecularly activated prodrugs, Drug Metab. Rev., 30, 787, 1998.
139. Wang, W., Jiang, J., Ballard, C. E., and Wang, B., Prodrug approaches to the improved delivery of peptide prodrugs, Curr. Pharmaceut. Design, 5, 265, 1999.
140. Greenwald, R. B., Choe, Y. H., Conover, C. D., Zhao, Shum, K., Wu, D., and Royzen, M., Drug delivery systems based on trimethyl lock lactonization: Poly(ethylene glycol) pro-drugs of amine containing compounds, script J sign. Med. Chem., 43, 475, 2000.
141. Christenson, I., Alkaline hydrolysis of some carbamic acid esters, Acta Chem. Scand., 18, 904, 1964.
142. Bender, M. L. and Homer, R. B., The mechanism of the alkaline hydrolysis of p-Nitrophenyl script N sign-Methylcarbamate, script J sign. Org. Chem., 30, 3975, 1965.
143. Bailon, P. S. and Palleroni, A. V., Interferon conjugates, European Patent Application, EP 0 809 996 A2, 1997.
144. Greenwald, R. B. and Martinez, A., Non-antigenic branched polymer conjugates, PCT WO 95/11924.
145. Martinez, A., Pendri, A., and Greenwald, R. B., Branched poly(ethylene glycol) linkers, Macromol. Chem. Phys., 198, 2489, 1997.
146. Monfardini, C., Schiavon, O., Caliceti, P., Morpurgo, M., Harris, J. M., and Veronese, F. M., A branched monomethoxypoly (ethylene glycol) for protein modification, Bioconjug. Chem., 6, 62, 1995.
147. Monfardini, C. and Veronese, F. M., Stabilization of substances in circulation, Bioconjug. Chem., 9, 418, 1998.
148. Garman, A. J., and Kalindjian, S. B., The preparation and properties of novel reversible PEG 5,000 protein conjugates, FEBS Lett., 223, 361, 1987.